Acumen Pharmaceuticals Investor Relations Material
Latest events
Q3 2024
Acumen Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Acumen Pharmaceuticals Inc
Access all reports
Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company primarily engaged in the discovery and development of therapies for the treatment of Alzheimer's disease. The company's most advanced candidate is ACU193, a humanized monoclonal antibody designed to target toxic soluble amyloid-beta oligomers. These amyloid-beta oligomers are associated with the neurodegeneration seen in Alzheimer’s disease patients. Acumen Pharmaceuticals was founded in 1996 and focuses on progressing its immunotherapy approach to offer potential disease-modifying treatments. The company is headquartered in Charlottesville, Virginia, and its shares are listed on the NASDAQ.
Key slides for Acumen Pharmaceuticals Inc
Q3 2024
Acumen Pharmaceuticals Inc
J.P. Morgan 42nd Annual Healthcare Conference 2024
Acumen Pharmaceuticals Inc
Latest articles
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
ABOS
Country
🇺🇸 United States